舒泰神(300204.SZ):STSP-0902滴眼液(用於治療神經營養性角膜炎)I期臨牀試驗完成首例受試者給藥
格隆匯10月22日丨舒泰神(300204.SZ)公佈,公司於2024年07月收到了國家藥品監督管理局簽發的STSP-0902滴眼液用於治療神經營養性角膜炎的《藥物臨牀試驗批准通知書》(通知書編號2024LP01513、2024LP01514、2024LP01515),同意本品開展神經營養性角膜炎的臨牀試驗。
近日,STSP-0902滴眼液在首都醫科大學附屬北京同仁醫院完成了針對神經營養性角膜炎I期臨牀試驗的首例受試者給藥。STSP-0902是舒泰神自主研發的對特定位點進行定向改造的重組人神經生長因子Fc融合蛋白,臨牀前實驗數據表明,STSP-0902能夠激活TrkA受體通路,促進神經生長,提高大鼠神經營養性角膜炎模型的角膜完整性和角膜神經長度,增加角膜知覺敏感度。同時,與重組野生型人神經生長因子相比,STSP-0902亦能夠減弱引起的疼痛反應。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.